RELIEF THERAPEUTICS Holding SA Announces Approved Resolutions in Extraordinary General Meeting

GENEVA, April 26, 2024 – RELIEF THERAPEUTICS Holding SA disclosed the outcomes of its extraordinary general meeting held in Geneva on Friday. The meeting saw shareholders endorse all presented resolutions with significant majority votes, surpassing 85%. Among the key decisions were the addition of three new board members and several strategic measures promoting corporate flexibility and governance adjustments.

In crucial resolutions, the election brought Mr. Peter de Svastich, Mr. Gregory Van Beek, and Mr. Thomas Elzinga into the board, with their tenure extending to June 2024. Concurrently, Ms. Patrice Jean and Mr. Thomas Plitz wrapped up their terms. Additionally, a capital reduction and increase in conditional share capital were endorsed, setting the nominal share capital to CHF 1'404'083.70 and expanding conditional capital to 7 million shares respectively.

The extension of the capital band to the same number of shares and its validity period until April 2029 were also affirmed. Importantly, the compensation packages for executive and board roles for the forthcoming periods were approved, setting clear financial outlines for corporate governance. Support was also reiterated for amendments to the Articles of Association, aligning with new Swiss corporate law requirements.